



## Breast Cancer: Clinical Trial and Translational Research

Guest Editors:

**Dr. Hirokazu Tanino**

Division of Breast Surgery,  
Department of Surgery,  
Wakayama Medical University,  
Wakayama, Japan

**Dr. Masayuki Nagahashi**

Department of Surgery, Division  
of Breast and Endocrine Surgery,  
Hyogo Medical University,  
Nishinomiya, Japan

**Dr. Akari Murakami**

Department of Breast Center,  
Ehime University Hospital, Ehime  
791-0204, Japan

Deadline for manuscript  
submissions:

**closed (23 October 2023)**

### Message from the Guest Editors

Dear Colleagues,

Researchers discover the seeds of new medical technologies and treatments in basic research. Translational research refers to research conducted with the aim of commercializing these seeds of medicine into new medical technologies and drugs that can be used in actual medical institutions. Therefore, it covers a wide range of areas from preclinical to clinical development, including not only therapeutic drugs but also technologies for detecting breast cancer, assisting surgery, and so on.

In this SPECIAL EDITION, we hope that you will publish data that are in the process of proving excellent technology, in a state that is about to go from the lab to the clinic. We look forward to receiving submissions from many of you.

Dr. Hirokazu Tanino

Dr. Masayuki Nagahashi

Dr. Akari Murakami

*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)